These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 31077950)

  • 1. Effect of icosapent ethyl on stroke risk: Different strokes for different folks?
    Lee M; Ovbiagele B
    J Neurol Sci; 2019 Jun; 401():127. PubMed ID: 31077950
    [No Abstract]   [Full Text] [Related]  

  • 2. Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT.
    Singh N; Bhatt DL; Miller M; Steg PG; Brinton EA; Jacobson TA; Jiao L; Tardif JC; Mason RP; Ballantyne CM;
    J Am Coll Cardiol; 2022 Jan; 79(2):220-222. PubMed ID: 35027114
    [No Abstract]   [Full Text] [Related]  

  • 3. Icosapent ethyl for hypertriglyceridemia: insights from the REDUCE-IT Trial.
    Miller M
    Future Cardiol; 2019 Nov; 15(6):391-394. PubMed ID: 31524535
    [No Abstract]   [Full Text] [Related]  

  • 4. The cost-effectiveness of omega-3 polyunsaturated fatty acids - The Australian healthcare perspective.
    Gao L; Moodie M; Li SC
    Eur J Intern Med; 2019 Sep; 67():70-76. PubMed ID: 31285124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides.
    Pareek M; Mason RP; Bhatt DL
    Expert Opin Drug Saf; 2022 Jan; 21(1):31-42. PubMed ID: 34253137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular risk reduction with icosapent ethyl.
    Patel PN; Patel SM; Bhatt DL
    Curr Opin Cardiol; 2019 Nov; 34(6):721-727. PubMed ID: 31464773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Icosapent Ethyl (Vascepa) for Hyperlipidemia/Hypercholesterolemia to Reduce Risk of Heart Attack and Stroke.
    Myran L; Nguyen TN
    Am Fam Physician; 2021 Jan; 103(2):117-118. PubMed ID: 33448769
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT.
    Burger PM; Bhatt DL; Dorresteijn JAN; Koudstaal S; Mosterd A; Martens FMAC; Steg PG; Visseren FLJ;
    Eur Heart J Cardiovasc Pharmacother; 2024 Oct; 10(6):488-499. PubMed ID: 38678009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
    Chapman MJ; Zamorano JL; Parhofer KG
    Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
    Brinton EA; Ballantyne CM; Guyton JR; Philip S; Doyle RT; Juliano RA; Mosca L
    J Womens Health (Larchmt); 2018 Sep; 27(9):1170-1176. PubMed ID: 29583081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of cardiovascular risk with icosapent ethyl (Vascepa).
    Med Lett Drugs Ther; 2020 Feb; 62(1591):17-18. PubMed ID: 32022786
    [No Abstract]   [Full Text] [Related]  

  • 12. Icosapent ethyl: a review of its use in severe hypertriglyceridemia.
    Kim ES; McCormack PL
    Am J Cardiovasc Drugs; 2014 Dec; 14(6):471-8. PubMed ID: 25428605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
    Kedia AW; Lynch E
    Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
    Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Gregson J; Pocock SJ; Ballantyne CM;
    J Am Coll Cardiol; 2019 Jun; 73(22):2791-2802. PubMed ID: 30898607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
    Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Ballantyne CM;
    N Engl J Med; 2019 Jan; 380(1):11-22. PubMed ID: 30415628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Icosapent ethyl for hypertriglyceridaemia and atherosclerosis: greater RESPECT for increased therapeutic use.
    Gaba P; Bhatt DL; Boden WE
    Eur Heart J; 2024 Feb; 45(6):439-442. PubMed ID: 37889071
    [No Abstract]   [Full Text] [Related]  

  • 17. Catch of the Day: Icosapent Ethyl for Reducing Cardiovascular Risk.
    Dixon DL
    Am J Med; 2020 Jul; 133(7):802-804. PubMed ID: 32243872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date.
    Jia X; Koh S; Al Rifai M; Blumenthal RS; Virani SS
    Vasc Health Risk Manag; 2020; 16():1-10. PubMed ID: 32021223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT.
    Gaba P; Bhatt DL; Giugliano RP; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Tardif JC; Ballantyne CM; Pinto DS; Budoff MJ; Gibson CM
    J Am Coll Cardiol; 2021 Oct; 78(15):1525-1537. PubMed ID: 34620410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results.
    Budoff MJ; Muhlestein JB; Bhatt DL; Le Pa VT; May HT; Shaikh K; Shekar C; Kinninger A; Lakshmanan S; Roy SK; Tayek J; Nelson JR
    Cardiovasc Res; 2021 Mar; 117(4):1070-1077. PubMed ID: 32609331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.